Table 3.
Principal baseline features of patients included
| Characteristics | n (%) |
|---|---|
| RT intent | |
| Ablative | 19 (47.5) |
| Palliative | 21 (52.5) |
| Initial staging | |
| Synchronous metastases | 15 (37.5) |
| Metachronous metastases | 25 (62.5) |
| Metastatic site | |
| Bone | 22 (55) |
| Brain | 7 (17.5) |
| Visceral | 7 (17.5) |
| Nodal | 3 (7.5) |
| Soft tissues | 1 (2.5) |
| IMDC risk group | |
| Favorable | 15 (37.5) |
| Intermediate/poor | 25 (62.5) |
| Cytoreductive nephrectomya | |
| Yes | 14 (93.3) |
| No | 1 (6.7) |
| Treatment lines before Nivolumab | |
| 0 | 5 (12.5) |
| 1 | 25 (62.5) |
| ≥ 2 | 10 (25) |
aPercentages are related to patients with synchronous metastasis at diagnosis